U.S. markets closed

Fidelity Disruptive Medicine Fund (FMEDX)

Nasdaq - Nasdaq Delayed Price. Currency in USD
Add to watchlist
12.20+0.09 (+0.74%)
At close: 8:00PM EST

Fidelity Disruptive Medicine Fund

Fidelity Summer Street Trust

82 Devonshire Street

Boston, MA 02109

Management Information
Niamh Brodie-Machura,Lead Manager since July 30, 2020
Charlie Hebard is co-manager of each fund, which he has managed since April 2020. He also manages other funds. Since joining Fidelity Investments in 1999, Mr. Hebard has worked as a managing director of research and portfolio manager. Prior to joining Fidelity, Hebard was an assistant vice president for CiticorpSecurities Inc. in the Global Media and Communications division, from 1996 to 1997.
Morningstar Style Box
Yahoo partners with Morningstar a leading market research and investment data group to help investors rate and compare funds on Yahoo Finance. The Morningstar Category is shown next to the Morningstar Style Box which identifies a fund's investment focus, based on the underlying securities in the fund.
Morningstar Category
While the investment objective stated in a fund's prospectus may or may not reflect how the fund actually invests, the Morningstar category is assigned based on the underlying securities in each portfolio. Morningstar categories help investors and investment professionals make meaningful comparisons between funds. The categories make it easier to build well-diversified portfolios, assess potential risk, and identify top-performing funds. We place funds in a given category based on their portfolio statistics and compositions over the past three years. If the fund is new and has no portfolio history, we estimate where it will fall before giving it a more permanent category assignment. When necessary, we may change a category assignment based on recent changes to the portfolio.

Fund Overview

Fund FamilyFidelity Investments
Net Assets35.33M
YTD ReturnN/A
Morningstar RatingN/A1
Inception DateApr 15, 2020

Fund Operations

Last DividendN/A
Last Cap GainN/A
Holdings TurnoverN/A
Average for CategoryN/A

Fees & Expenses

ExpenseFMEDXCategory Average
Annual Report Expense Ratio (net)1.00%1.21%
Prospectus Net Expense Ratio1.00%N/A
Prospectus Gross Expense Ratio1.00%N/A
Max 12b1 FeeN/AN/A
Max Front End Sales LoadN/A5.37%
Max Deferred Sales LoadN/A1.20%
3 Yr Expense Projection318N/A
5 Yr Expense Projection0N/A
10 Yr Expense Projection0N/A